Key facts
- This page summarizes RA CAPITAL MANAGEMENT, L.P.'s Form 4 filing for Solid Biosciences Inc. (SLDB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Feb 2025, 16:11.
RA CAPITAL MANAGEMENT, L.P. - 19 Feb 2025 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- SLDB
- Reported as of
- 19 Feb 2025
- Net transaction value
- +$14,996,280
- SEC form
- 4
- Accepted by SEC
- 21 Feb 2025, 16:11:22 UTC
- Prior SEC filing
- 24 Feb 2025
- Next SEC filing
- 07 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RA CAPITAL MANAGEMENT, L.P. filed Form 4 for Solid Biosciences Inc. (SLDB) on 21 Feb 2025.
Change
- Previous filing in this sequence was filed on 24 Feb 2025.
- Current net transaction value: +$14,996,280.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLDB
transaction
Derivative
Pre-Funded Warrants (Right to Buy)
Purchase
- Transaction value
- $14,996,280
- Shares
- +3,722,085
- Change %
- Price
- $4.03
- Shares after
- 3,722,085
- Date
- 19 Feb 2025
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 3,722,085
- Exercise price
- $0.001000
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
RA CAPITAL MANAGEMENT, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
Footnote F2
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Footnote F3
Held directly by the Fund.